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Medicine and Surgery, Federico II University. PAbstract Background and aims: Uric acid (UA) is a byproduct of the high-energy purine meta-
bolism and is conventionally regarded as a marker of cardio-metabolic impairment. Its potential
relationship with energy homeostasis is unknown to date.
Methods and results: In a cross-sectional study on 121 otherwise healthy obese and 99 sex- and-
age-matched lean subjects, UA levels were analyzed in relation to metabolic health, inflamma-
tory markers, respiratory quotient (RQ) and resting energy expenditure (REE) as assessed by in-
direct calorimetry, fat mass (%FM) and fat-free mass (FFM) as determined by bioimpedance
analysis.
As expected, obese and lean subjects differed in BMI, glucolipid homeostasis, leptin and insulin
levels, inflammatory markers, %FM and FFM (p < 0.001 for all). Likewise, UA levels (p < 0.001)
and rates of hyperuricaemia (40.5% vs 3.0%, p < 0.0001) were also higher in obese than lean con-
trols. Further, indirect calorimetry confirmed that obesity increased REE and decreased RQ signif-
icantly (p < 0.001). Beyond the expected metabolic correlates, in individual and merged groups
UA levels were associated negatively with RQ and positively with REE (p < 0.0001 for both). In
multivariable regression analysis, significant independent predictors of UA were BMI and sex.
When BMI was replaced by measures of body composition, %FM and FFM emerged as significant
predictors of serum UA (p < 0.0001).
Conclusions: A potential link relates serum UA to measures of resting energy expenditure and
their determinants.
ª 2018 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.Introduction
Mostmammals excrete uric acid (UA), a byproduct of purine
degradation [1], upon conversion to soluble allantoin by the
liver enzyme urate oxidase (uricase) [2]. In humans, the lack
of uricase causes UA accumulation [3] and promotesneral Medicine, IRCCS Istituto
ia Italy. Fax: þ390323514409.
.uniupo.it (P. Marzullo).
logy, the Italian Society for the Study of A
ublished by Elsevier B.V. All rights reservehyperuricemia, under the influence of inappropriate dietary
and life-style factors [4]. Upon urate super-saturation,
crystalline monosodium urate becomes susceptible to pre-
cipitation leading to potentially serious complications, such
as gout and kidney disease [5]. Non-crystalline soluble
component of UA possesses a unique amphipathic action [6]
and exerts pro-oxidant effects in vascular cells mediated by
lipid oxidation, which can lead to endothelial dysfunction
and cardiovascular disease [7]. On the other hand, soluble
UA acts as a powerful antioxidant that scavenges oxygentherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical
d.
1030 C. Mele et al.singlets and oxygen radicals, peroxynitrite, and chelates
transition metals, thus protecting the cell membrane and
DNA from oxidative damage [8].
Physiologically, UA levels are higher in men than
women, increase with age and menopause, and change
under the influence of antiuricosuric drugs (i.e. thiazide
diuretics) or medications able to reduce UA levels (i.e.
losartan and long-acting Ca channel blockers) [9e13].
Obesity is a condition associated with a typical metabolic
phenotype [14] and promotes UA accumulation increas-
ingly referred to as a proxy of the so-called metabolic
syndrome [15], due to its robust association with obesity,
visceral adipose tissue (VAT) accumulation, insulin resis-
tance, systemic inflammation and muscle mass [16e18].
Obesity-associated hyperuricaemia is prompted by a
number of mechanisms, including the following: over-
expression of xanthine oxidoreductase in adipose tissue,
which results in enhanced purine catabolism and
increased production of UA [19]; hyperinsulinaemia and
insulin resistance, which decrease renal UA excretion [20];
3) VAT accumulation, which promotes fatty acid (FA)
output in the portal vein [21] and, as a result of the
excessive metabolic outflow, promotes de novo synthesis
of purine from NADPH in the pentose phosphate pathway
and increased UA production [16,22]; increased con-
sumption of purine-rich food, especially meat and to a
lesser extent fish, alcoholic drinks and soft drinks rich in
fructose [23]. Blood UA reflects the balance between pu-
rine dietary uptake, production and catabolism of purines,
and production and excretion of UA. Although purine
turnover is relatively constant at 300e400 mg/day, dietary
factors accelerate purine nucleotide depletion and rates of
de novo purine synthesis, thus potentiating UA production
[24]. De novo purine biosynthesis is a high-energy process
that leads to the conversion of phosphoribosyl pyrophos-
phate (PRPP) to inosine monophosphate (IMP) through 10
enzymatic activities and consumption of 6 ATP molecules,
whereas only one ATP molecule is required for the purine
salvage pathway consumption [25,26]. Thus, production
and excretion of UA in humans reflects energy utilization
and could act as a surrogate measure of fuel utilization and
energy homeostasis. On this basis, we sought to explore if
UA could reflect energy storage by investigating the rela-
tionship between circulating UA and the components of
energy metabolism, e.g. respiratory quotient (RQ) and
resting energy expenditure (REE), in a cross-sectional
analysis in lean and obese adult individuals.
Methods
Patients
This study consecutively enrolled 121 obese patients (52
males; age 18e58 yr; body mass index (BMI), 43.1 7.1 kg/
m2) referred to our Institution for work-up and rehabili-
tation of obesity and its comorbidities, and 99 matched
lean subjects (34 males; age 19e53 yr; BMI, 22.5  2.5 kg/
m2). All women were premenopausal, as assessed by per-
sonal history of regular menses. Exclusion criteria for bothgroups included medications interfering with UA levels
and hypertriglyceridemia. Patients were also excluded if
suffering from autoimmune diseases, neoplasms, poly-
cythemia, hemolysis, diabetes mellitus, liver or kidney
diseases. All participants reported alcohol consumption
<125 ml daily. The investigation was approved by the ad
hoc Ethical Research Committee of Istituto Auxologico
Italiano, functioning according to the 3rd edition of the
Guidelines on the Practice of Ethical Committees in Med-
ical Research. Written consent was obtained from all pa-
tients and controls, after full explanation of the purpose
and nature of the study.
Body measurements
All subjects underwent body measurements wearing light
underwear, in fasting conditions after voiding. Weight and
height were measured to the nearest 0.1 kg and 0.1 cm,
respectively, using standard methods. BMI was expressed
as body mass (kg)/height (m)2. Obesity was defined for any
BMI over 30 kg/m2.
The respiratory quotient (RQ; VO2/VCO2) and resting
energy expenditure (REE; kcal/24 h) were determined in a
thermoregulated room (22e24 C) by computed open-
circuit indirect calorimetry, measuring resting oxygen
uptake and resting carbone dioxide production by a
ventilated canopy (Sensormedics, Milan, Italy) at 1-min
intervals for 30 min and expressed as a 24-h value, as
previously reported [27]. The test consists of making each
patient lie down relaxed on a comfortable armchair, with
the head under a transparent hood connected to a pump,
which applies an adjustable ventilation through it. Exhaled
gas dilutes with the fresh air ventilated under the hood
and a sample of this mixture is conveyed to the analyzers,
through a capillary tube and analyzed. Ambient and
diluted fractions of O2 and CO2 are measured for a known
ventilation rate, and O2 consumption (VO2) and CO2
production (VCO2) are determined. Energy expenditure
was calculated according to the Weir equation [28]:
EE Z 5.68 VO2 þ 1.59 VCO2 e 2.17 Nu. As short-term
urinary collections to assess total nitrogen excretion (Nu)
may not be representative of the protein oxidized during
the measurement itself, they were not be obtained in this
study, and assumed to be 13 g/24 h [29]. The predicted REE
(pREE) was calculated by the Harris-Benedict formula and
allowed to test for metabolic efficiency, calculated as the
ratio between measured/predicted REE values, as previ-
ously reported [30].
Percent fat body mass (FM) and lean body mass (FFM)
were determined by bioelectrical impedance analysis (BIA)
(model BIA 101/S Akern, Florence, Italy). Patients with fluid
overload according to vectorial analysis were excluded to
minimize errors in estimating FM and FFM in severe
obesity [31].
Assays
Blood samples were drawn under fasting conditions
(8e12 h). Each participant was required to avoid strenuous
Table 1 Summary of anthropometric, metabolic and biochemical
parameters in lean subjects and obese patients. Significance be-
tween groups was calculated by ManneWhitney test for continuous
variables or the chi-square for categorical variables.
Parameters Obese subjects Lean subjects p
Males/Females 52/69 34/65 0.2
Age (years) 35.1  9.1 35.3  7.9 0.8
BMI (Kg/m2) 43.1  7.1 22.5  2.5 <0.001
WC (cm) 121.0  26.5 85.0  14.8 <0.001
FM (%) 45.0  6.7 24.9  6.4 <0.001
FFM (kg) 66.7  17.7 47.6  8.5 <0.001
RQ (VO2/VCO2) 0.84  0.08 0.90  0.12 <0.001
REE (Kcal/24 h) 2054  432 1577  255 <0.001
pREE (Kcal/24 h) 2119  471 1469  203 <0.001
REE/pREE 0.98  0.10 1.08  0.13 <0.001
UA (mg/dL) 6.49  1.51 4.32  1.19 <0.001
CHO (mg/dL) 201  35 199  37 0.6
HDL CHO (mg/dL) 47  16 64  16 <0.001
LDL CHO (mg/dL) 135  33 132  84 0.6
TG (mg/dL) 155  79 94  43 <0.001
Insulin (mIU/mL) 14.2  7.3 9.7  8.8 <0.001
Glucose (mg/dL) 84.6  13.6 86.0  14.5 0.4
HOMA-IR 3.05  1.78 1.94  1.42 <0.001
CRP (mg/dL) 0.93  0.96 0.19  0.32 <0.001
Fibrinogen (mg/dL) 407.7  66.9 305.5  67.8 <0.001
Leptin (mg/mL) 33.92  15.18 8.95  7.83 <0.001
For abbreviations: BMI, body mass index; WC, waist circumference;
TBW, total body water; FM, fat mass; FFM, free fat mass; RQ, Res-
piratory Quotient; REE, resting energy expenditure; pREE, predicted
resting energy expenditure; UA, uric acid; CHO, total cholesterol;
HDL, high density lipoprotein; LDL, low density lipoprotein; TG,
triglycerides; HOMA-IR, homeostatic model of insulin resistance;
CRP, C-reactive protein.
--- 1031physical activity, caffeine and dietary supplements 24 h
prior to testing.
Blood levels of UA, glucose, total cholesterol, high-
density (HDL) and low-density (LDL) lipoprotein choles-
terol and triglycerides were measured by enzymatic
methods (Roche Diagnostics, Mannheim, Germany). Serum
insulin levels were measured using a Cobas Integra 800
Autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA).
Ultrasensitive C-reactive protein was measured by CRP
(latex) HS Roche kit. Hyperuricemia was defined as above
7 mg/dL in men and above 6 mg/dL in women [32].
Insulin resistance was calculated by the homeostasis
model of assessment-insulin resistance (HOMA-IR)
approach, calculated as insulin (microunits per milliliter) x
blood glucose (millimoles per liter)/22.5. Serum leptin
levels were measured by enzyme-linked immunosorbent
assay (Human Leptin ELISA, Mediagnost, Reutlingen, Ger-
many). The minimum detectable concentration was 0.2 ng/
mL. The intra-assay and inter-assay coefficients of varia-
tion were <10%.
Statistical analysis
Statistical analysis was performed using SPSS version 21
(Somers, NY, USA). Values are expressed as
means  standard deviation (SD). Continuous variables
were log transformed if distribution resulted skewed by
the ShapiroeWilk normality test. Comparative analyses
within and between groups were performed by
ManneWhitney U test or two-tailed unpaired Student’s t
test after Welch’s correction, when appropriate. The sim-
ple chi-square test was used for associations between
categorical variables. Spearman’s correlation analysis was
used to identify significant associations between variables
of interest. Stepwise multivariable regression analysis was
used to evaluate the independent association of variations
in UA with metabolic, anthropometric or biochemical pa-
rameters. b coefficients and related significance values
obtained from the models are reported. Two-sided
p < 0.05 was considered as statistically significant.
Results
A summary of anthropometric, metabolic an biochemical
data is reported in Table 1. As expected, obese and lean
subjects differed formeasures of adiposity, glucose and lipid
metabolism, inflammatory markers, as well as leptin levels.
Compared to lean individuals, obese patients also hadhigher
REE and lower RQ values. Higher UA levels and rates of hy-
peruricemia (40.5% vs 3.0%; c2 Z 40.6, p < 0.0001) were,
predictably, observed in obese compared to control subjects.
Correlation analyses between UA levels and variables of in-
terest in the population as a whole and in separate groups
(Table 2) showed that UA levels were higher in males and,
overall, positively associated with glucolipid parameters,
inflammatory markers, fat and lean body mass and other
anthropometric variables relating to visceral adiposity. Both
in merged and separate groups, an evident correlation was
noted between serum UA and FFM. Nevertheless,correlations obtained in the entire dataset were lost after
controlling for gender, age and BMI. When serum UA was
plotted against components of energy homeostasis, the
pattern of association relating UA to RQ and REE was sig-
nificant but divergent. In fact, a negative association was
documented between serum UA and RQ values, which per-
sisted after controlling for gender, age and BMI. This asso-
ciation was, however, not significant in separate groups.
When REE was accounted for, a positive relationship was
observed betweenUA levels and REE (Fig.1), whichwas also
significant in separate groups and remained unalteredwhen
REE was normalized by FFM (rho Z 0.13, p < 0.05). After
controlling for BMI, age and gender as individual covariates,
the association between REE and UA remained significant,
whereas it was abrogated when these variables were
included collectively in analysis (data not shown).
Based on the above-mentioned correlations, a number
of stepwise multivariable regression models were per-
formed that included UA levels as the dependent variable
and metabolic, anthropometric and body composition
parameters as independent variables. With the purpose of
avoiding collinearity, different models were built that
comprised either BMI or FFM and %FM, either RQ or REE, in
addition to sex (0 Z males, 1 Z females), HOMA-IR, HDL
cholesterol and triglycerides as the independent variables
(Table 3). In all models thus built, neither RQ nor REE
entered the regression equations.
Table 2 Spearman’s correlation analysis between serum UA levels and variables of interest in merged groups (whole), obese patients and lean
subjects. For significance: a, p < 0.05; b, p < 0.01; c, p < 0.001; d, p < 0.0001.
Parameters Whole population Obese subjects Lean controls
Age (years) 0.07 0.15 0.04
BMI (Kg/m2) 0.64d 0.25b 0.38d
WC (cm) 0.74d 0.44d 0,57d
FM (%) 0.43d L0.34d 0.12
FFM (kg) 0.73d 0.50d 0.60d
RQ (VO2/VCO2) L0.32d 0.02 0.11
REE (Kcal/24 h) 0.66d 0.46d 0.47d
CHO (mg/dL) 0.11 0.14 0.11
HDL CHO (mg/dL) L0.54d L0.29c L0.34d
LDL CHO (mg/dL) 0.24d 0.14 0.23a
TG (mg/dL) 0.43d 0.27b 0.16
Insulin (mIU/mL) 0.44d 0.38d 0.04
Glucose (mg/dL) 0.05 0.05 0.36d
HOMA-IR 0.44d 0.36d 0.11
CRP 0.47d 0.02 0.06
Fibrinogen (mg/dL) 0.34d 0.03 0.11
Leptin (mg/mL) 0.36d 0.23a 0.39d
For abbreviations: BMI, body mass index; TBW, total body water; FM, fat mass; FFM, free fat mass; RQ, Respiratory Quotient; REE, resting energy
expenditure; CHO, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglycerides; HOMA-IR, homeostatic model
of insulin resistance; CRP, C-reactive protein. Bold values indicate significance.
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The results of our study show that serum UA not only
reflects metabolic phenotype but also acts as a surrogate
index of the resting energy state in lean and obese sub-
jects. We observed that UA levels were inversely associ-
ated with values of RQ and increased with increasing
values of REE. In multivariate analysis, neither RQ nor REEFigure 1 Bivariate correlation analysis between serum UA levels and
RQ (upper panel) or REE (lower panel) in merged datasets from obese
subjects and lean controls. Open circles and dashed line: obese sub-
jects; closed circles and broken line: lean controls.acted as independent predictors of UA levels, suggesting
that stronger metabolic determinants rule overall UA
levels in the circulation.
UA is a recognized marker of metabolic derangement
widely used for its ability to predict the risk of cardio-
metabolic morbidity [33,34]. Dietary excess, fat accumu-
lation, insulin resistance and metabolic syndrome are all
known causes of increased UA, which enhance the risk of
gout and kidney disease. Different studies recently
demonstrated an interesting association between serum
UA and insulin resistance mediated by adiposity [35,36],
providing the new concept that UA could reflect different
components of metabolic syndrome. A previous study in
NHANES participants showed a 1.3e1.5 times greater risk
of gout in overweight individuals after adjustment for
serum UA, while the prevalence ratio was 1.8 for class ITable 3 Regression coefficients derived from the stepwise multi-
variable regression of UA levels. Beta standardized coefficients are
shown for models built depending on non-collinear independent
variables. For significance:*, p < 0.05,**; p < 0.001;***, p < 0.0001.
Variables Beta standardized coefficient
Model 1 Model 2 Model 3 Model 4
Sex 0.370*** 0.321*** 0.379*** 0.321***
BMI (kg/m2) 0.604*** e 0.591*** e
FM (%) e 0.399*** e 0.363***
FFM (kg) e 0.340*** e 0.296**
REE (Kcal/24 h) e e 0.056 0.065
RQ (VO2/VCO2) 0.110 0.099 e e
HOMA-IR 0.046 0.038 0.065 0.047
HDL (mg/dL) 0.021 0.056 0.023 0.020
TG (mg/dL) 0.092 0.105 0.101 0.113*
For abbreviations: BMI, body mass index; HDL, high density lipo-
protein; HOMA-IR, homeostatic model of insulin resistance; FM, fat
mass; FFM, free fat mass; RQ, Respiratory Quotient; REE, resting
energy expenditure; TG, triglycerides.
--- 1033obesity and 2.2e2.4 for class II or III obesity [37]. Epide-
miologic studies have thus extensively described the
ability of serum UA to act as a surrogate measure of car-
diometabolic disorders, e.g. hypertension, coronary artery
disease, cerebrovascular disease, and kidney disease, with
this link being not entirely explained by overt hyperuri-
cemia but also by absolute UA levels at the high-normal
range [38]. Such relationship is here confirmed, as UA
levels clustered with adiposity-related variables and the
cardiometabolic markers presently investigated. One novel
finding was the divergent association observed between
UA levels and components of energy homeostasis. In
keeping with the finding that RQ values were lower in
obese than lean subjects, which likely originates from the
effects of fat mass on the rate of FA oxidation [39], we
documented that RQ values were linearly and inversely
associated with UA levels. This relationship was not
influenced by hyperuricaemia, i.e. subjects with hyper-
uricaemia did not show lower RQ levels that those
without. Nevertheless, the association between RQ and UA
lost significance in analysis on separate groups, likely due
to the narrow regression of RQ values. RQ, which repre-
sents the moles of carbon evolved per mole of oxygen
consumed, reflects macronutrients metabolism [39]. In
humans, RQ values of 0.7, 0.8 and 1.0 conventionally
indicate oxidation of lipids, proteins and carbohydrates,
respectively [40]. As such, the inverse association seen
between UA and RQ in our cohort could reflect a pre-
dominant lipid oxidation occurring in the obese group.
There is evidence that UA production and lipid metabolism
are related in gout [41]. Moreover, adipose tissue sampled
from obese patients shows active FA synthesis [42] and de
novo purine synthesis [43] through activation of the
pentose phosphate pathway, which promotes UA synthesis
and excretion [44]. On the other hand, lipolysis is up-
regulated in obese-derived adipose tissue [45], and a
high content of FA may flow into the liver directly through
the portal vein in subjects with visceral fat accumulation,
thereby accelerating TG synthesis and promoting hyper-
triglyceridemia [46]. According to this view, we too
observed that UA associated with plasma TG and abdom-
inal adiposity. Hence, it can be hypothesized that UA could
signal the rate of FA oxidation, e.g. the switch from
glycolysis to lipolysis.
Another result worth of mention was the positive as-
sociation between serum UA and REE values. This associ-
ation occurred both in single and merged group analysis.
At the multivariable regression analysis, REE was excluded
from the regression equations, suggesting that anthropo-
metric variables maintain greater control of UA levels. It
remains difficult to conceptualize on these results based
on the general lack of similar data in the literature. Liter-
ature search only revealed one abstract reporting on a
similar positive correlation between serum UA and REE in
obese women [47]. It has long been shown that resting
energy expenditure varies among people independent of
body size and composition, and that skeletal muscle
metabolism is the main determinant of metabolic rate.
Therefore, differences in resting muscle metabolism canproduce differences in metabolic rates among individuals
[48]. While it could be hypothesized that the positive as-
sociation linking UA and REE reflects differences in lean
mass between obese and control subjects, since both FFM
and UA are increased in obesity [18], the correlation was
unchanged when REE was adjusted for FFM, suggesting
that FFM does not directly influence the association be-
tween UA and REE. It should be stated, however, that we
measured body composition by BIA, which is per se less
informative than DXA due to the potential effect of fluid
overload. Literature data suggests that UA, as a marker of
cell metabolism, can increase in conditions associated with
high REE such as hyperthyroidism [49], HIV-related
infection [50], and hypoxia resulting from chronic
obstructive pulmonary disease or sleep apnea [51]. As we
did not assess sleep apnea in our obese patients, this issue
remains open.
Under condition of adipose tissue accumulation, like in
obesity, adipocyte differentiation promotes intracellular
accumulation of triglycerides and secretion of UA [19],
suggesting that the intracellular activation of the pentose
phosphate pathway relating to synthesis of FA is accom-
panied with the enhanced activity of the xanthine oxido-
reductase and consequent production of UA [19]. Purines,
endogenous modulators of energy metabolism and signal
transduction, play important roles in the physiology of
platelets, muscles and neurotransmission [52]. De novo
purine biosynthesis is a high-energy event that leads to
the conversion of phosphoribosyl pyrophosphate (PRPP) to
inosine monophosphate (IMP) through a process requiring
10 enzymatic activities and 6 ATP molecules, while only
one ATP molecule is required for the purine salvage
pathway [25]. Thus, UA production could provide an in-
direct estimate of ATP degradation. Because any increase in
energy expenditure for a given amount of substrate re-
quires either increased ATP hydrolysis or decreased ATP
synthesis [53], UA could be involved in signaling ATP
availability, hence the energy state to other organs or ap-
paratuses. As independent factor, UA has been already
shown to mediate its effects by inducing oxidative stress,
inflammation, endothelial dysfunction and activation of
the renin angiotensin aldosterone system, which play a
role in the pathogenesis of cardiovascular disease [54].
Our study has some important limitations that should
be mentioned. Firstly, we did not determine UA excretion
in urine, which would allow us to compare the excretion
rate and circulating UA levels so as to avoid the effect of UA
retention in obese vs lean individuals. Secondly, we did not
measure ATP levels, which could allow us to discuss the
role of UA as an indirect measure of ATP degradation.
Thirdly, the cross-sectionality of the study does not allow
to define causality of the association between UA and
components of energy metabolism. Finally, we could
assess a “one-to-one” matching of participants based on
the retrospective nature of our study. Notwithstanding
these limitations, this study has important strengths,
including the accurate analysis of REE, the inclusion of pre-
menopausal women and the evaluation of multiple
anthropometric and biochemical parameters.
1034 C. Mele et al.In summary, UA could be one of those factors that signal
the systemic oxidative phosphorylation and are able to
fine tune the energy state required for cell differentiation
and metabolic requirements. Further studies are war-
ranted to clarify if the relationship between UA and REE
reflects a functional link or acts as an adaptive physio-
logical response to abnormal substrates oxidation.Funding
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